Drug intelligence / Profile preview

GO321

Development stage: Phase 1
Lead developer: GeneSail Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral, Intraperitoneal

Overview

GO321 is a recombinant oncolytic virus developed by GeneSail Biotech (Shanghai) Co., Ltd. for the treatment of advanced refractory solid tumors. It is designed to selectively infect and replicate within malignant cells, leading to direct oncolysis and the release of tumor-associated antigens. This process, combined with the potential expression of therapeutic transgenes, stimulates a systemic anti-tumor immune response. GO321 is currently being evaluated in Phase I clinical trials involving intratumoral or intracavitary administration to assess its safety, tolerability, and preliminary efficacy in patients who have progressed after standard-of-care therapies.

Beyond the preview

Go deeper on GO321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO321.

Explore the full profile